Application of surface‑enhanced laser desorption/ionization time‑of‑flight mass spectrometry technology for the diagnosis of colorectal adenoma

Zhou,Zhong‑Yin; Tao,Di‑Di; Cao,Ji‑Wang; Luo,He‑Sheng

doi:10.3892/ol.2013.1304

Application of surface‑enhanced laser desorption/ionization time‑of‑flight mass spectrometry technology for the diagnosis of colorectal adenoma

Authors:
- Zhong‑Yin Zhou
- Di‑Di Tao
- Ji‑Wang Cao
- He‑Sheng Luo
View Affiliations

Affiliations: Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: April 15, 2013 https://doi.org/10.3892/ol.2013.1304
Pages: 1935-1938

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to identify a specific biological marker for the diagnosis of colorectal adenomas through the analysis of variations in serum protein profiling in colorectal adenoma patients. The study was conducted at the Renmin Hospital of Wuhan University (Wuhan, China) between September 2011 and May 2012. Surface‑enhanced laser desorption/ionization time‑of‑flight mass spectrometry (SELDI‑TOF‑MS) was performed to compare the serum protein profiles of 50 patients with colorectal adenoma and 50 healthy individuals. The obtained protein profiles were analyzed using Biomarker Wizard software. Twenty protein peaks were identified to exhibit differences in average intensity between colorectal adenomas compared with normal controls, including peaks 8,565.84, 8,694.51 and 5,910.50 Da, in which the intensity between the patients and control individuals was significantly different. Two peaks, 8,565.84 and 8,694.51 Da, were observed to be highly expressed in the colorectal adenomas, however, expression was low in the control samples. By contrast, 5,910.50 Da expression was low in the colorectal adenomas and high in the controls. The results of the current study indicate that the three protein peaks may represent specific biomarkers for colorectal adenomas.

View Figures

View References

1	Hasan N, Pollack A and Cho I: Infectious causes of colorectal cancer. Infect Dis Clin North Am. 24:1019–1039. 2010. View Article : Google Scholar
2	Thirlwell C, Will OC, Domingo E, et al: Clonality assessment and clonal ordering of individual neoplastic crypts shows polyclonality of colorectal adenomas. Gastroenterology. 138:1441–1454. 2010. View Article : Google Scholar : PubMed/NCBI
3	Winawer SJ, Zauber AG, Ho MN, et al: Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med. 329:1977–1981. 1993. View Article : Google Scholar : PubMed/NCBI
4	Arber N, Spicak J, Rácz I, et al: Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial. Am J Gastroenterol. 106:1135–1146. 2011.PubMed/NCBI
5	Leung WK, Tang V and Lui PC: Detection rates of proximal or large serrated polyps in Chinese patients undergoing screening colonoscopy. J Dig Dis. 13:466–471. 2012. View Article : Google Scholar : PubMed/NCBI
6	Hortin GL: The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem. 52:1223–1237. 2006. View Article : Google Scholar : PubMed/NCBI
7	Terracciano R, Pasqua L, Casadonte F, et al: Derivatized mesoporous silica beads for MALDI-TOF MS profiling of human plasma and urine. Bioconjug Chem. 20:913–923. 2009. View Article : Google Scholar : PubMed/NCBI
8	Zheng SZ and Zou SQ: The application of comparative proteomics in study of tumor marker. Zhong Guo Pu Wai Ji Chu Yu Lin Chuang Za Zhi. 12:147–149. 2008.
9	Gast MC, Schellens JH and Beijnen JH: Clinical proteomics in breast cancer: a review. Breast Cancer Res Treat. 116:17–29. 2009. View Article : Google Scholar : PubMed/NCBI
10	Ahram M: An introduction into proteomics and its clinical applications. Saudi Med J. 28:499–507. 2007.PubMed/NCBI
11	Xu SY, Liu Z, Ma WJ, Sheyhidin I, Zheng ST and Lu XM: New potential biomarkers in the diagnosis of esophageal squamous cell carcinoma. Biomarkers. 14:340–346. 2009. View Article : Google Scholar : PubMed/NCBI
12	Issaq HJ, Fox SD, Chan KC and Veenstra TD: Global proteomics and metabolomics in cancer biomarker discovery. J Sep Sci. 34:3484–3492. 2011. View Article : Google Scholar : PubMed/NCBI
13	Schipper R, Loof A, de Groot J, Harthoorn L, Dransfield E and van Heerde W: SELDI-TOF-MS of saliva: methodology and pre-treatment effects. J Chromatogr B Analyt Technol Biomed Life Sci. 847:45–53. 2007. View Article : Google Scholar : PubMed/NCBI
14	Fuchs B, Schiller J, Süss R, et al: Analysis of stem cell lipids by offline HPTLC-MALDI-TOF MS. Anal Bioanal Chem. 392:849–860. 2008. View Article : Google Scholar : PubMed/NCBI
15	Sun CY, Zang YC, San YX, Sun W and Zhang L: Proteomic analysis of clear cell renal cell carcinoma. Identification of potential tumor markers. Saudi Med J. 31:525–532. 2010.PubMed/NCBI
16	Schipper R, Loof A, de Groot J, Harthoorn L, van Heerde W and Dransfield E: Salivary protein/peptide profiling with SELDI-TOF-MS. Ann NY Acad Sci. 1098:498–503. 2007. View Article : Google Scholar : PubMed/NCBI
17	Grizzle WE, Semmes OJ, Basler J, et al: The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology. Urol Oncol. 22:337–343. 2004. View Article : Google Scholar
18	Brenner H, Chang-Claude J, Rickert A, Seiler CM and Hoffmeister M: Risk of colorectal cancer after detection and removal of adenomas at colonoscopy: population-based case-control study. J Clin Oncol. 30:2969–2976. 2012. View Article : Google Scholar : PubMed/NCBI
19	Rüth S, Spatz J and Anthuber M: Colorectal adenoma: pro conventional/laparoscopic resection. Chirurg. 82:520–525. 2011.(In German).